<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110844">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01757665</url>
  </required_header>
  <id_info>
    <org_study_id>2012-02</org_study_id>
    <nct_id>NCT01757665</nct_id>
  </id_info>
  <brief_title>ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform</brief_title>
  <acronym>COMMENCE</acronym>
  <official_title>ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of the Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to confirm that the modifications to tissue processing, valve
      sterilization and packaging do not raise any new questions of safety and effectiveness in
      subjects who require replacement of their native or prosthetic aortic or mitral valve.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, non-randomized, non-controlled observational clinical trial. Up to
      650 subjects will be enrolled at up to 35 participating clinical sites. The trial will
      include male and female patients, 18 years or older, requiring replacement for a diseased,
      damaged, or malfunctioning native or prosthetic aortic or mitral valve. Patients will be
      followed and assessed after implant for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>When 400 patient years for each valve position has been achieved - approx. December 2016</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Descriptive information of early rates and late linearized rates of:
Structural valve deterioration
Thromboembolism
Valve thrombosis
All bleeding/hemorrhage
Major bleeding/hemorrhage
All paravalvular leak
Major paravalvular leak
Non-structural valve deterioration
Endocarditis
All cause mortality
Trial valve-related mortality
Trial valve-related reoperation
Explant
Hemolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effectiveness Endpoints</measure>
    <time_frame>Up to 5-Years at each scheduled follow-up visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinically acceptable hemodynamic performance confirmed by core lab evaluation of echocardiography
New York Heart Association (NY-HA) functional class compared to baseline
Change in Quality of Life questionnaire Short Form 12 version 2 (SF-12v2) from baseline/screening to POD 390</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">650</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Mitral Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aortic/Mitral valve replacement therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M</intervention_name>
    <description>Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M</description>
    <arm_group_label>Bioprosthesis: Aortic Model 11000A/ Mitral Model 11000M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is 18 years or older

          2. Provides written informed consent prior to trial procedures

          3. Agrees to attend all follow-up assessments for up to 5 years and is willing to comply
             with specified follow-up evaluations at clinical investigational sites that are
             participating in the COMMENCE trial and/or obtain the protocol-specified diagnostic
             tests at centers that are under the same IRB

          4. Diagnosed with aortic or mitral valve disease requiring valve replacement based on
             pre- operative evaluation

          5. Scheduled to undergo planned aortic or mitral valve replacement with or without
             concomitant bypass surgery

          6. Scheduled to undergo planned aortic valve replacement with or without resection and
             replacement of the ascending aorta from the sinotubular junction and without the need
             for circulatory arrest for hemi arch or arch replacement

        Exclusion criteria:

          1. Requires emergency surgery

          2. Requires multiple valve replacement/ repair

          3. Has prior valve surgery, which included implant of a bioprosthetic valve, mechanical
             valve, or annuloplasty ring that will remain in situ

          4. Requires a surgical procedure outside of the cardiac area (e.g. vascular bypass)

          5. Requires surgical replacement of the aortic root

          6. Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months to
             the scheduled aortic or mitral valve replacement surgery

          7. Has renal insufficiency as determined by creatinine (S-Cr) level ≥ 2.5 mgdL or
             end-stage renal disease requiring chronic dialysis at screening visit

          8. Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient
             ischemic attack (TIA) within 6 months (180 days) prior to planned valve surgery

          9. Has acute myocardial infarction (MI) within 30 days prior to planned valve surgery

         10. Has presence of non-cardiac disease limiting life expectancy to less than 12 months

         11. Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM)

         12. Diagnosed with abnormal calcium metabolism and/or hyperparathyroidism

         13. Exhibits left ventricular ejection fraction  ≤ 20% as validated by diagnostic
             procedure prior to planned valve surgery

         14. Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation

         15. Hemodynamic or respiratory instability requiring inotropic support, mechanical
             circulatory support, or mechanical ventilation within 30 days prior to planned valve
             surgery

         16. Documented leukopenia (WBC &lt; 3.5x 103/µL), acute anemia (Hgb &lt; 10.0 gm/dL or 6
             mmol/L), thrombocytopenia (platelet count &lt; 50x103/µL) or history of bleeding
             diathesis or coagulopathy

         17. Has prior organ transplant or is currently an organ transplant candidate

         18. Current or recent participation (within 6 weeks prior to surgery) in another drug or
             device trial

         19. Was previously implanted with trial device (Model 11000A or Model 11000M)

         20. Pregnant (female subject of childbearing potential only), lactating or planning to
             become pregnant during the duration of participation in trial

         21. Currently incarcerated or unable to give voluntary informed consent

         22. Documented history of substance (drug or alcohol) abuse within the last 5 years prior
             to implant

         23. Requires concomitant left ventricular assist device (LVAD) placement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Puskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Hospital Midtown</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Svensson, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Organizational Affiliation: The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce Van Deman</last_name>
    <phone>949-250-2626</phone>
    <email>bruce_van_deman@ewards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gita Ghadimi, OD</last_name>
    <phone>949-250-5872</phone>
    <email>gita_ghadimi@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia Vasquez-Caldera, RN</last_name>
      <phone>323-442-6225</phone>
      <email>leticia.vasquez-caldera@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Vaughn Starnes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Robertson, RN</last_name>
      <phone>352-273-5510</phone>
      <email>Debra.Robertson@surgery.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Charles Klodell, MD</last_name>
      <phone>352-273-5501</phone>
      <email>charles.klodell@surgery.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Klodell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Mansker, RN</last_name>
      <phone>407-303-7556</phone>
      <email>Beverly.Mansker@flhosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Tracey Purvis, RN</last_name>
      <phone>407-303-7556</phone>
      <email>Tracey.Purvis@flhosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Accola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Baio, MSN</last_name>
      <phone>404-686-3374</phone>
      <email>kbaio@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Neill, RN</last_name>
      <phone>404-686-3575</phone>
      <email>alexis.neill@emory.eduedu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Halkos, MD, FACS, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Barnett, RN</last_name>
      <phone>317-583-7804</phone>
      <email>lbarnett@corvascmds.com</email>
    </contact>
    <contact_backup>
      <last_name>Andrew Scroggs, Research Director</last_name>
      <phone>317-338-9380</phone>
      <email>RASCROGG@stvincent.org</email>
    </contact_backup>
    <investigator>
      <last_name>David A Heimansohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susie Page, RN</last_name>
      <phone>913-588-9720</phone>
      <email>spage3@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dominique Dziedzic</last_name>
      <phone>913-945-6445</phone>
      <email>ddziedzic@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>George &quot;Trip&quot; Zorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Villanueva, MPA</last_name>
      <phone>410-328-9409</phone>
      <email>rvillanueva@smail.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cindi Young, RN</last_name>
      <phone>410-328-8149</phone>
      <email>cyoung@smail.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James S Gammie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine Holen, RN</last_name>
      <phone>616-391-5067</phone>
      <email>jeanine.holen@spectrum-health.org</email>
    </contact>
    <contact_backup>
      <last_name>Julie Bishop, RN</last_name>
      <phone>616-391-2727</phone>
      <email>julie.bishop@spectrumhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tomasz A Timek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyn Goldsmith, MA RN BSN CCRC</last_name>
      <phone>212-342-0261</phone>
      <email>lg2240@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Alonso, CCRC</last_name>
      <phone>212-342-4539</phone>
      <email>aa2974@columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hiroo Takayama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Kahn, RN</last_name>
      <phone>212-746-5594</phone>
      <email>rek9015@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim O'Brien</last_name>
      <phone>212-746-5194</phone>
      <email>kmk9002@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leonard Girardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya-El Mandel-Portnoy, M. Sc</last_name>
      <phone>212-241-8905</phone>
      <email>yael.mandel-Portnoy@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Robin Varghese, MD</last_name>
      <phone>212-659-9490</phone>
      <email>Robin.varghese@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>David Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Garcia, RN,BSN</last_name>
      <phone>216-444-7753</phone>
      <email>GARCIAM1@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Geither, RN, CCRP</last_name>
      <phone>216-445-6916</phone>
      <email>GEITHEC@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Lars Svensson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacie Hanes, CRC</last_name>
      <phone>405-608-1280</phone>
      <email>shanes@okheart.com</email>
    </contact>
    <contact_backup>
      <last_name>Julia Myers, RN</last_name>
      <phone>405-628-6288</phone>
      <email>jmyers@okheart.com</email>
    </contact_backup>
    <investigator>
      <last_name>Goya Raikar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Fondren</last_name>
      <phone>832-355-9942</phone>
      <email>fondren@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tunu Magwe</last_name>
      <phone>713-798-8393</phone>
      <email>ttenende@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Todd K Rosengart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krzysztof Bartus, Dr. Med</last_name>
      <phone>+48 5022 94 250</phone>
      <email>coolchris@interia.pl</email>
    </contact>
    <contact_backup>
      <last_name>Maciek Bochenek, Dr. Med</last_name>
      <phone>+48 6065 15 870</phone>
      <email>mbochenek@poczta.fm</email>
    </contact_backup>
    <investigator>
      <last_name>Jerzy Sadowski, Prof. Dr. Med</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Kardiologii im. Prymasa Tysiqclecia Stefana</name>
      <address>
        <city>Warsaw</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agata Bilewska, MD, PhD</last_name>
      <phone>+48(22)8154901</phone>
      <email>agatabilewska@o2.pl</email>
    </contact>
    <contact_backup>
      <last_name>Mariusz Kusmierczyk, MD, PhD</last_name>
      <phone>+48(22)3434610</phone>
      <email>mkusmierczyk1971@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jacek Rozanski, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Mitral valve replacement</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Mitral Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
